The short version of anti-doping fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-12-18. Anything still debated is marked as such rather than presented as settled.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
=== United Kingdom === A Chick-fil-A operated in Edinburgh during the Spring of 2018. On October 10, 2019, Chick-fil-A returned to Europe, with the opening of a store at The Oracle shopping centre in Reading, UK. The store closed in March 2020 after The Oracle opted not to continue the lease of the location beyond the six-month pilot period in the face of continued protests over the chain's anti-LGBTQ stance. In February 2019, Chick-fil-A opened a store on a 12-month pilot scheme in Aviemore, Scotland. The store was closed in January 2020 amidst protests and controversy from locals and customers regarding the chain's former donations to charities supporting anti-LGBT rights causes. Chick-fil-A said that they had always planned a short-term stay at the location. Later, the company changed some policies, appointing its first head of diversity in 2020, and focused its charitable activities on education and hunger alleviation rather than opponents of same-sex marriage. In September 2023, the company planned to open five restaurants in the UK from early 2025, investing over $100M over the following ten years in the UK. The chain said that it would apply its charitable policies, including a $25,000 donation to a local organization on opening a Chick-fil-A restaurant and donation of surplus food to local charitable causes, to its UK branches too.
There was a mass solanine poisoning incident in 1979 in the U.K., when 78 adolescent boys at a boarding school exhibited symptoms after eating potatoes that had been stored improperly over the summer. Seventeen of them ended up hospitalized, but they all recovered. The potatoes were determined to have between 0.25 and 0.3 mg of solanine per gram of potato. Another mass poisoning was reported in Canada in 1984, after 61 schoolchildren and teachers showed symptoms of solanine toxicity after consuming baked potatoes with 0.5 mg of solanine per gram of potato.
Genipin is a chemical compound found in Genipa americana fruit extract. It is an aglycone derived from an iridoid glycoside called geniposide which is also present in fruit of Gardenia jasminoides. Genipin is an excellent natural cross-linker for proteins, collagen, gelatin, and chitosan cross-linking. It has a low acute toxicity, with LD50 i.v. 382 mg/kg in mice, therefore, much less toxic than glutaraldehyde and many other commonly used synthetic cross-linking reagents. Furthermore, genipin can be used as a regulating agent for drug delivery, as the raw material for gardenia blue pigment preparation, and as the intermediate for alkaloid syntheses. In vitro experiments have shown that genipin blocks the action of the transporter uncoupling protein 2.
Galloway told The Independent on Sunday in June 2012: "I am not a pacifist. I am a revolutionary. I am a Socialist who doesn't like Capitalism and who likes Imperialism less. ... I support the armed struggle where there is no alternative." In a 2002 interview with The Guardian, Galloway said he had supported the Soviet Union and said that its end was "the biggest catastrophe of my life". By 2013, he described himself on Twitter as "pro-Palestine, anti-war, pro-equality, anti-Islamophobia". In 2024, Galloway identified as socially conservative, and in 2025 he said he "no longer want[s] to hear [himself] described as a leftist", adding that "it now means liberalism, licence, ‘refugees welcome here’ and so on. All this is inimical to the interests of the working class". Writing for The Guardian in 2024, Michael Chessum argued that Galloway's politics had shifted in the latter half of the 2010s, embracing Scottish unionism and social conservatism alongside more typically leftist positions, and highlighting the involvement of the socially conservative Communist Party of Great Britain (Marxist–Leninist) in the early years of the Workers Party. Chessum likened Galloway's political evolution to that of German politician Sahra Wagenknecht, a leading member of The Left who broke away to found her own eponymous political movement, and who similarly espouses socially conservative positions and anti-NATO views.
=== Presymbiosis === To form an ectomycorrhizal connection, the fungal hyphae must first grow towards the plant's roots. Then they must envelope and penetrate the root cap cells and infect them, allowing the symbiotic Hartig net and associated structures to form. Both partners (plant and fungus) must follow a precise sequence of gene expression for this to be successful. There is evidence that communication between the partners in the early stage of ectomycorrhiza occurs in some cases via volatile organic compounds produced only during the interaction phase, and that genes involved in secretory, apical growth, and infection processes show changes in expression early in the pre-contact phase. Thus, a complex set of molecular changes appears to take place even before the fungus and host plant make contact. The plant hosts release metabolites into the rhizosphere that can trigger basidiospore germination, growth of hyphae towards the root, and the early steps of EcM formation. These include flavonoids, diterpenes, cytokinins, hormones and other nutrients. Some host-released metabolites have been shown to stimulate fungal growth in Pisolithus, modify the branching angle of hyphae, and cause other changes in the fungus. Some fungal genes appear to be expressed before plant contact, suggesting that signals in the soil may induce important fungal genes at a distance from the plant.
Sources: en.wikipedia.org
During the beta phase, the game underwent multiple updates, introducing new weapons and a completely redesigned interface based on Valve's VGUI2 technology. Additionally, the official bot, developed by Turtle Rock Studios for Counter-Strike: Condition Zero, was publicly tested within Counter-Strike 1.6 from June 5. After more than six months of public testing, the beta phase concluded on September 9, 2003. The final release of Counter-Strike 1.6 was initially scheduled for the following day, but last-minute changes to the Steam network caused a brief delay. The final version, along with the Steam client, was officially launched on September 12, 2003. Following release, advertisements were brought to Counter-Strike. They were removed after the game was converted to the SteamPipe content delivery system. Plans for Counter-Strike 1.7—which aimed to merge the player bases of Counter-Strike and Condition Zero—were never realized. In February 2013, Valve ported Counter-Strike onto OS X and Linux. It is the second Valve game to be ported to Linux, after Team Fortress 2.
Adipose tissue is an endocrine organ that secretes numerous protein hormones, including leptin, adiponectin, and resistin. These hormones generally influence energy metabolism, which is of great interest to the understanding and treatment of type 2 diabetes and obesity. Their relative roles in modifying appetite, insulin resistance and atherosclerosis are the subjects of intense research, as they may be modifiable causes of morbidity in people with obesity.
Returning American strike pilots generally assessed these carriers as more crippled than they actually were, mistaking for devastating direct hits what Japanese post-war records revealed to have actually been huge geysers caused by near misses. The battleship Haruna was also hit by two bombs, including one directly on a main battery turret. Damage was contained, and she was able to keep station because her captain promptly called to flood the turret's magazine to avoid the possibility of an explosion. Twenty American aircraft in the strike were destroyed by Japanese fighters and anti-aircraft fire that made up for a relative lack of accuracy with high volume of fire. After the protracted strike, it became clear that most of the aircraft returning to their carriers were running dangerously low on fuel, and to worsen matters, night had fallen. At 20:45, the first returning U.S. aircraft reached TF 58. Knowing his aviators would have difficulty finding their carriers, Admiral Joseph J. Clark of Hornet decided to illuminate his carrier, shining searchlights directly up into the night, despite the risk of attack from Japanese submarines and night-flying aircraft. Mitscher backed up the decision, and soon every ship in Task Force 58 was lit up, in spite of the risks involved. Picket destroyers fired starshells to help the aircraft find the task groups. Planes were given clearance to land on any available flight deck (not just their home carriers, as usual), and many did land on other carriers. Despite this, 80 of the returning aircraft were lost.
===== Electrode ===== In 2010, researchers first reported creating a graphene-silicon heterojunction solar cell, where graphene served as a transparent electrode and introduced a built-in electric field near the interface between the graphene and n-type silicon to help collect charge carriers. In 2012 researchers reported efficiency of 8.6% for a prototype consisting of a silicon wafer coated with trifluoromethanesulfonyl-amide (TFSA) doped graphene. Doping increased efficiency to 9.6% in 2013. In 2015 researchers reported efficiency of 15.6% by choosing the optimal oxide thickness on the silicon. This combination of carbon materials with traditional silicon semiconductors to fabricate solar cells has been a promising field of carbon science. In 2013, another team reported 15.6% percent by combining titanium oxide and graphene as a charge collector and perovskite as a sunlight absorber. The device is manufacturable at temperatures under 150 °C (302 °F) using solution-based deposition. This lowers production costs and offers the potential using flexible plastics. In 2015, researchers developed a prototype cell that used semitransparent perovskite with graphene electrodes. The design allowed light to be absorbed from both sides. It offered efficiency of around 12 percent with estimated production costs of less than $0.06/watt. The graphene was coated with PEDOT:PSS conductive polymer (polythiophene) polystyrene sulfonate). Multilayering graphene via CVD created transparent electrodes reducing sheet resistance.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.